New HCPCS Level II Codes Effective July 1
- By admin aapc
- In CMS
- April 9, 2012
- Comments Off on New HCPCS Level II Codes Effective July 1
The Centers for Medicare & Medicaid Services (CMS) have made several changes to the HCPCS Level II code set, revising two codes and adding several more, effective July 1.
Two codes now covered by carrier discretion will no longer be covered:
J1680 Injection, human fibrinogen concentrate, 100 mg
J9001 Injection, doxorubicin HCl, all lipid formulations, 10 mg
The following codes are being added, with coverage left to carrier discretion:
Q2034 Influenza virus vaccine, split virus, for intramuscular use (Agriflu)
Q2045 Human fibrinogen concentrate, 1 mg
Q2046 Injection, aflibercept, 1 mg
Q2047 Injection, peginesatide, 0.1 mg (for ESRD on dialysis)
Q2048 Injection, doxorubicin hydrochloride, liposomal imported lipodox, 10 mg
Q2049 Injection, doxorubicin hydrochoride, liposomal, imported lipodox, 10 mg
One new code will not be covered by Medicare:
S1090 Mometasone furoate sinus implant, 370 micrograms
- Correctly Identify Low Back Pain - March 1, 2023
- How to Optimize the RCM Process - February 1, 2023
- It Pays to Participate in AAPC’s Annual Salary Survey - September 1, 2022
800-626-2633
Referencing the codes for Doxil, according to CMS, Q2049 is to be used for the imported Lipodox, Q2048 descriptor reads Doxorubicin Hydrochloride, Liposomal, Doxil 10mg.